Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEKTAR THERAPEUTICSNKTR · Entity 4364 | SVP & Chief Operating Officer | August 16, 2019 | August 19, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEKTAR THERAPEUTICS
Report date August 16, 2019 · Filed August 19, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 162,759 |
Reported balance
After 2019-08-16 transaction · row 1
1 source rowRow 1 · 2019-08-16 · Sale · Disposed 3,819 · Balance 162,759 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2: This transaction was executed in multiple trades at prices ranging from $17.87 to $18.37. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2: This transaction was executed in multiple trades at prices ranging from $17.87 to $18.37. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 16, 2019 Filed Aug 19, 2019 23:07 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 3,819 | $18.15 | $69,314.85 |
DisclosureSEC source: 0001209191-19-046718 · doc4.xml · nonDerivative · entry 1 Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,759 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $17.87 to $18.37. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| May 16, 2019 Filed May 18, 2019 00:21 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 4,077 | $31.37 | $127,895.49 |
DisclosureSEC source: 0001209191-19-031188 · doc4.xml · nonDerivative · entry 1 Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,578 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.86 to $32.68. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| February 19, 2019 Filed Feb 22, 2019 01:15 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 3,822 | $42.39 | $162,014.58 |
DisclosureSEC source: 0001209191-19-012335 · doc4.xml · nonDerivative · entry 1 Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,655 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $41.90 to $42.96. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| January 28, 2019 Filed Jan 30, 2019 23:02 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 63,000 | $10.69 Strike: $10.69 | $673,470.00 |
DisclosureSEC source: 0001209191-19-006044 · doc4.xml · derivative · entry 3 Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 63,000 shares Expires 2019-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Nicholson for certain options expiring on February 7, 2019. Read SEC document |
| January 28, 2019 Filed Jan 30, 2019 23:02 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 63,000 | $42.82 | $2,697,660.00 |
DisclosureSEC source: 0001209191-19-006044 · doc4.xml · nonDerivative · entry 2 Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,477 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Nicholson for certain options expiring on February 7, 2019. F2 · price: This transaction was executed in multiple trades at prices ranging from $42.31 to $43.55. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| January 28, 2019 Filed Jan 30, 2019 23:02 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 63,000 | $10.69 | $673,470.00 |
DisclosureSEC source: 0001209191-19-006044 · doc4.xml · nonDerivative · entry 1 Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,477 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Nicholson for certain options expiring on February 7, 2019. Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 23:14 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 5,982 | $38.25 | $228,811.50 |
DisclosureSEC source: 0001209191-18-059293 · doc4.xml · nonDerivative · entry 1 Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,477 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $37.47 to $38.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| August 16, 2018 Filed Aug 17, 2018 01:46 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Disposition to issuerCommon Stock | 8,137 | $58.40 | $475,200.80 |
DisclosureSEC source: 0001209191-18-047242 · doc4.xml · nonDerivative · entry 2 Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,459 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $56.37 to $59.72. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 01:46 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 65,000 | $0.00 Strike: $56.90 | $0.00 |
DisclosureSEC source: 0001209191-18-047242 · doc4.xml · derivative · entry 3 Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2025-12-14 F4 · security: These options, at the time of their grant were subject to both performance-based and time-based vesting requirements. On August 15, 2018, the performance-based condition vesting was satisfied. The time-based vesting is on a monthly pro-rata basis over a period of four years from the grant date (December 15, 2017). F5 · date: These stock options were granted on December 15, 2017 and the performance-based vesting requirement for these stock options was satisfied on August 15, 2018 upon the Compensation Committee's certification of the successful acceptance of the New Drug Application by the FDA for NKTR-181. F6 · derivative.exercise_date: This stock option vests on a monthly pro-rata basis over a period of four years from the grant date. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 01:46 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 26,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-047242 · doc4.xml · nonDerivative · entry 1 Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,596 F1 · security: Represents restricted stock units ("RSUs"), convertible on a one-for-one basis into shares of Common Stock of the Company. These RSUs, at the time of their grant on December 15, 2017, were subject to both performance-based and time-based vesting requirements. On August 15, 2018, the performance-based condition vesting was satisfied. The time-based vesting is on a quarterly pro-rata basis over a period of three (3) years from the date of grant. Read SEC document |
| May 16, 2018 Filed May 18, 2018 23:05 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 4,917 | $83.39 | $410,028.63 |
DisclosureSEC source: 0001209191-18-031596 · doc4.xml · nonDerivative · entry 1 Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,596 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $81.35 to $84.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| March 07, 2018 Filed Mar 8, 2018 23:09 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 100,144 | $100.45 | $10,059,464.80 |
DisclosureSEC source: 0001209191-18-018221 · doc4.xml · nonDerivative · entry 2 Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,513 F2 · price: This transaction was executed in multiple trades at prices ranging from $99.00 to $101.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 23:09 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 120,000 | $98.29 | $11,794,800.00 |
DisclosureSEC source: 0001209191-18-018221 · doc4.xml · nonDerivative · entry 1 Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,657 F1 · price: This transaction was executed in multiple trades at prices ranging from $98.00 to $100.04. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 00:09 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 4,879 | $82.94 | $404,664.26 |
DisclosureSEC source: 0001209191-18-011595 · doc4.xml · nonDerivative · entry 1 Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 387,657 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $81.57 to $84.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 23:03 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 120,000 | $0.00 Strike: $11.34 | $0.00 |
DisclosureSEC source: 0001209191-18-007139 · doc4.xml · derivative · entry 2 Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 120,000 shares Expires 2018-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made for stock options scheduled to expire on February 1, 2018. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 23:03 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 120,000 | $11.34 | $1,360,800.00 |
DisclosureSEC source: 0001209191-18-007139 · doc4.xml · nonDerivative · entry 1 Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 392,536 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made for stock options scheduled to expire on February 1, 2018. Read SEC document |
| December 15, 2017 Filed Dec 19, 2017 23:28 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 65,000 | $0.00 Strike: $56.90 | $0.00 |
DisclosureSEC source: 0001209191-17-066481 · doc4.xml · derivative · entry 2 Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2025-12-14 F2 · derivative.exercise_date: This stock option vests over four years in equal monthly installments based on continued service. Read SEC document |
| December 15, 2017 Filed Dec 19, 2017 23:28 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 26,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-066481 · doc4.xml · nonDerivative · entry 1 Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,536 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. These RSUs vest over three years in substantially equal quarterly installments based on continued service. Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 23:05 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Disposition to issuerCommon Stock | 6,620 | $44.23 | $292,802.60 |
DisclosureSEC source: 0001209191-17-061594 · doc4.xml · nonDerivative · entry 2 Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,536 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $41.98 to $45.47. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 23:05 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 50,000 | $0.00 Strike: $14.41 | $0.00 |
DisclosureSEC source: 0001209191-17-061594 · doc4.xml · derivative · entry 3 Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2024-12-12 F5 · security: These options, at the time of their grant were subject to both performance-based and time-based vesting requirements. On November 15, 2017, the performance-based condition vesting was satisfied. The time-based vesting is on a monthly pro-rata basis over a period of four years from the grant date (December 13, 2016). F6 · date: These stock options were granted on December 13, 2016 and the performance-based vesting requirement for these stock options was satisfied on November 15, 2017 upon the Compensation Committee's certification of the successful acceptance of the New Drug Application by the FDA for Ciprofloxacin Dry Powder Inhalation (Cipro CPI). F7 · derivative.exercise_date: This stock option vests on a monthly pro-rata basis over a period of four years from the grant date. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 23:05 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-061594 · doc4.xml · nonDerivative · entry 1 Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,156 F1 · security: Represents restricted stock units ("RSUs"), convertible on a one-for-one basis into shares of Common Stock of the Company. These RSUs, at the time of their grant on December 13, 2016, were subject to both performance-based and time-based vesting requirements. On November 15, 2017, the performance-based condition vesting was satisfied. The time-based vesting is on a quarterly pro-rata basis over a period of three (3) years from the date of grant. F2 · date: These restricted stock units ("RSUs") were granted on December 13, 2016 and the performance-based vesting requirement for these RSUs was satisfied on November 15, 2017 upon the Compensation Committee's certification of the successful acceptance of the New Drug Application by the FDA for Ciprofloxacin Dry Powder Inhalation (Cipro DPI). Read SEC document |
| November 13, 2017 Filed Nov 15, 2017 23:02 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 25,000 | $0.00 Strike: $9.24 | $0.00 |
DisclosureSEC source: 0001209191-17-060974 · doc4.xml · derivative · entry 3 Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2017-11-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and is related to a stock option that was scheduled to expire on November 17, 2017. Read SEC document |
| November 13, 2017 Filed Nov 15, 2017 23:02 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 15,910 | $37.78 | $601,079.80 |
DisclosureSEC source: 0001209191-17-060974 · doc4.xml · nonDerivative · entry 2 Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,156 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and is related to a stock option that was scheduled to expire on November 17, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $36.58 to $41.12. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| November 13, 2017 Filed Nov 15, 2017 23:02 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 25,000 | $9.24 | $231,000.00 |
DisclosureSEC source: 0001209191-17-060974 · doc4.xml · nonDerivative · entry 1 Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,066 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and is related to a stock option that was scheduled to expire on November 17, 2017. Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 23:04 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 3,177 | $19.32 | $61,379.64 |
DisclosureSEC source: 0001209191-17-049667 · doc4.xml · nonDerivative · entry 1 Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,066 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $19.02 to $19.67. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| June 07, 2017 Filed Jun 9, 2017 22:02 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 150,000 | $0.00 Strike: $6.34 | $0.00 |
DisclosureSEC source: 0001209191-17-038973 · doc4.xml · derivative · entry 3 Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2017-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and is related to a stock option that was scheduled to expire on June 9, 2017. Read SEC document |
| June 07, 2017 Filed Jun 9, 2017 22:02 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 101,700 | $19.24 | $1,956,708.00 |
DisclosureSEC source: 0001209191-17-038973 · doc4.xml · nonDerivative · entry 2 Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,243 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and is related to a stock option that was scheduled to expire on June 9, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $18.83 to $19.74. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| June 07, 2017 Filed Jun 9, 2017 22:02 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 150,000 | $6.34 | $951,000.00 |
DisclosureSEC source: 0001209191-17-038973 · doc4.xml · nonDerivative · entry 1 Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,943 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and is related to a stock option that was scheduled to expire on June 9, 2017. Read SEC document |
| May 16, 2017 Filed May 19, 2017 00:49 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 3,146 | $19.55 | $61,504.30 |
DisclosureSEC source: 0001209191-17-033770 · doc4.xml · nonDerivative · entry 1 Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,943 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $19.31 to $19.90. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| February 16, 2017 Filed Feb 18, 2017 01:05 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 3,237 | $13.14 | $42,534.18 |
DisclosureSEC source: 0001209191-17-012407 · doc4.xml · nonDerivative · entry 1 Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,089 F1 · price: This transaction was executed in multiple trades at prices ranging from $12.94 to $13.72. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| February 10, 2017 Filed Feb 11, 2017 01:11 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $4.65 | $0.00 |
DisclosureSEC source: 0000899243-17-003648 · doc4.xml · derivative · entry 2 Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,000 shares Expires 2017-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This stock option became fully vested on February 23, 2013 and will expire on February 22, 2017 if not exercised. Read SEC document |
| February 10, 2017 Filed Feb 11, 2017 01:11 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 45,000 | $4.65 | $209,250.00 |
DisclosureSEC source: 0000899243-17-003648 · doc4.xml · nonDerivative · entry 1 Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,326 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2017 Filed Feb 6, 2017 22:20 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 8,505 | $0.00 Strike: $4.65 | $0.00 |
DisclosureSEC source: 0000899243-17-002871 · doc4.xml · derivative · entry 6 Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 8,505 shares Expires 2017-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The Reporting Person exercised and sold a portion of the Shares of common stock subject to this stock option that expires on February 22, 2017, with the objective of using substantially all of the proceeds to cover the exercise price of the entire stock option and applicable withholding taxes. F4 · derivative.exercise_date: This stock option became fully vested on February 23, 2013 and will expire on February 22, 2017 if not exercised. Read SEC document |
| February 03, 2017 Filed Feb 6, 2017 22:20 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 8,505 | $12.48 | $106,142.40 |
DisclosureSEC source: 0000899243-17-002871 · doc4.xml · nonDerivative · entry 4 Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,326 F1 · kind: The Reporting Person exercised and sold a portion of the Shares of common stock subject to this stock option that expires on February 22, 2017, with the objective of using substantially all of the proceeds to cover the exercise price of the entire stock option and applicable withholding taxes. F1 · shares: The Reporting Person exercised and sold a portion of the Shares of common stock subject to this stock option that expires on February 22, 2017, with the objective of using substantially all of the proceeds to cover the exercise price of the entire stock option and applicable withholding taxes. F3 · price: This price reflects the weighted average sale price for open-market sales of Shares made by the Reporting Person on February 3, 2017. The actual prices for these transactions range from $12.45 to $12.51, inclusive. Read SEC document |
| February 03, 2017 Filed Feb 6, 2017 22:20 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 8,505 | $4.65 | $39,548.25 |
DisclosureSEC source: 0000899243-17-002871 · doc4.xml · nonDerivative · entry 3 Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,831 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The Reporting Person exercised and sold a portion of the Shares of common stock subject to this stock option that expires on February 22, 2017, with the objective of using substantially all of the proceeds to cover the exercise price of the entire stock option and applicable withholding taxes. F1 · shares: The Reporting Person exercised and sold a portion of the Shares of common stock subject to this stock option that expires on February 22, 2017, with the objective of using substantially all of the proceeds to cover the exercise price of the entire stock option and applicable withholding taxes. Read SEC document |
| February 02, 2017 Filed Feb 6, 2017 22:20 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 66,495 | $0.00 Strike: $4.65 | $0.00 |
DisclosureSEC source: 0000899243-17-002871 · doc4.xml · derivative · entry 5 Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,505 Underlying: Common Stock · 66,495 shares Expires 2017-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The Reporting Person exercised and sold a portion of the Shares of common stock subject to this stock option that expires on February 22, 2017, with the objective of using substantially all of the proceeds to cover the exercise price of the entire stock option and applicable withholding taxes. F4 · derivative.exercise_date: This stock option became fully vested on February 23, 2013 and will expire on February 22, 2017 if not exercised. Read SEC document |
| February 02, 2017 Filed Feb 6, 2017 22:20 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 66,495 | $12.38 | $823,208.10 |
DisclosureSEC source: 0000899243-17-002871 · doc4.xml · nonDerivative · entry 2 Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,326 F1 · kind: The Reporting Person exercised and sold a portion of the Shares of common stock subject to this stock option that expires on February 22, 2017, with the objective of using substantially all of the proceeds to cover the exercise price of the entire stock option and applicable withholding taxes. F1 · shares: The Reporting Person exercised and sold a portion of the Shares of common stock subject to this stock option that expires on February 22, 2017, with the objective of using substantially all of the proceeds to cover the exercise price of the entire stock option and applicable withholding taxes. F2 · price: This price reflects the weighted average sale price for open-market sales of Shares made by the Reporting Person on February 2, 2017. The actual prices for these transactions range from $12.20 to $12.45, inclusive. The Reporting Person further undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of Shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| February 02, 2017 Filed Feb 6, 2017 22:20 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 66,495 | $4.65 | $309,201.75 |
DisclosureSEC source: 0000899243-17-002871 · doc4.xml · nonDerivative · entry 1 Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,821 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The Reporting Person exercised and sold a portion of the Shares of common stock subject to this stock option that expires on February 22, 2017, with the objective of using substantially all of the proceeds to cover the exercise price of the entire stock option and applicable withholding taxes. F1 · shares: The Reporting Person exercised and sold a portion of the Shares of common stock subject to this stock option that expires on February 22, 2017, with the objective of using substantially all of the proceeds to cover the exercise price of the entire stock option and applicable withholding taxes. Read SEC document |
| December 13, 2016 Filed Dec 16, 2016 01:45 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 50,000 | $0.00 Strike: $12.24 | $0.00 |
DisclosureSEC source: 0001209191-16-155520 · doc4.xml · derivative · entry 2 Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2024-12-12 F2 · derivative.exercise_date: This stock option vests over four years in equal monthly installments based on continued service. Read SEC document |
| December 13, 2016 Filed Dec 16, 2016 01:45 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-155520 · doc4.xml · nonDerivative · entry 1 Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,326 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. These RSUs vest over three years in equal quarterly installments based on continued service. Read SEC document |
| November 16, 2016 Filed Nov 18, 2016 23:11 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 1,654 | $13.96 | $23,089.84 |
DisclosureSEC source: 0001209191-16-151304 · doc4.xml · nonDerivative · entry 1 Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,326 F1 · price: This transaction was executed in multiple trades at prices ranging from $13.71 to $14.14. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.